Pliant Therapeutics (PLRX) Long-Term Debt Issuances (2022 - 2025)
Pliant Therapeutics (PLRX) posted quarterly Long-Term Debt Issuances of $32.3 million for Q4 2025, up 262.07% year-over-year from $8.9 million in Q4 2024, and up 262.07% quarter-over-quarter from -$19.9 million in Q4 2024.
Pliant Therapeutics (PLRX) Long-Term Debt Issuances (2022 - 2025) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Long-Term Debt Issuances for 3 consecutive years, with $32.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Debt Issuances rose 262.07% year-over-year to $32.3 million; the TTM figure through Dec 2025 stood at $32.3 million (changed N/A YoY), while the FY2025 annual figure was $32.3 million, changed N/A from the prior year.
- Long-Term Debt Issuances rose to $32.3 million in Q4 2025 per PLRX's latest filing, from -$19.9 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $32.3 million in Q4 2025 and bottomed at -$19.9 million in Q4 2024.
- Historically, Long-Term Debt Issuances has averaged $8.0 million across 3 years, with a median of $9.9 million in 2022.
- On a YoY basis, Long-Term Debt Issuances climbed as much as 262.07% in 2025 and fell as far as 262.07% in 2025.
- Pliant Therapeutics' Long-Term Debt Issuances stood at -$150000.0 in 2022, then slumped by 13172.67% to -$19.9 million in 2024, then jumped by 262.07% to $32.3 million in 2025.
- Business Quant data shows PLRX's Long-Term Debt Issuances at $32.3 million in Q4 2025, -$19.9 million in Q4 2024, and $19.9 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.27 Mn |
| Dec 31, 2025 | 32.27 Mn |
| Dec 31, 2024 | -19.91 Mn |
| Dec 31, 2024 | -19.91 Mn |
| Mar 31, 2024 | 19.91 Mn |
| Mar 31, 2024 | 19.91 Mn |
| Dec 31, 2022 | -150,000.00 |
| Dec 31, 2022 | -150,000.00 |